The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Cytopenias after axi-cel in R/R large B-cell lymphoma: clinical implications
Paolo Strati, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical implications of cytopenias 30 days or more after axicabtagene ciloleucel therapy in relapsed/refractory large B-cell lymphoma. He emphasizes the need for viral prophylaxis and monitoring of CD4+ cell counts. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
